SAM #CDC-75D301-Presolicitation-SMNVARRATS

Sole Source Safety Assessment of Rotavirus Vaccine Microneedle Patch in Rats

This opportunity involves a sole source contract by the CDC for safety assessment of a microneedle patch for rotavirus vaccination in rats. - CDC Office of Acquisition Services (HHS) intends to award to Southern Research Institute - Purpose: Assess safety of Live Attenuated Rotavirus Vaccine (LARV) Microneedle (MN) patch administered intradermally in rats - Four administrations per regulatory requirements - Sole source justification: Only one responsible source available; no other supplies/services will satisfy agency requirements - No specific OEMs or part numbers listed; this is a research/testing service - NAICS code: 541715 (R&D in Physical, Engineering, and Life Sciences) - Period of performance: Two years - Place of performance: Atlanta, Georgia - Not a competitive solicitation, but capability statements may be submitted for consideration

Description

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Centers for Disease Control and Prevention (CDC) National Center for Immunizations and Respiratory Diseases (NCIRD) intends to award a Firm Fixed Price Contract to Southern Research Institute, 2000 9th Avenue S; Birmingham, Alabama 35205. Under the authority of FAR 13.106-1(b)(1)(i) and 10 U.S.C. 2304(c) (1), only one responsible source and no other supplies or services will satisfy agency requirements. The objectives of this project will be to assess the safety of an Live Attenuated Rotavirus Vaccine (LARV) Microneedle (MN) patch for vaccination against rotavirus when given intradermally for four (4) administrations in rats in accordance with regulatory requirements.

The Period of Performance is from 5/15/2026 thru 05/14/2028.

The anticipated award date of this action is on or before May 15, 2026. The applicable NAICS code is 541715: Research and Development In The Physical, Engineering And Life Sciences (Except Nanotechnology And Biotechnology). This notice of intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the warranties and proof as being capable of providing the requesting services. Capability Statements shall not exceed 2 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. Capability Statements are due by 10:00 AM Eastern Standard Time (EST), April 9, 2026. Capability Statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to Tim Williams email address at: TPW8@cdc.gov NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.

View original listing